Megan Rigby

Megan Rigby

Auto-generated profile, based on publicly available information

Megan Rigby

Frederick National Laboratory for Cancer Research 2 NCI RAS Initiative, Cancer Research Technology Program Leidos Biomedical Research, Inc., Frederick, Maryland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Science Advances
Verified
Journal Article
Open access
MWMatthew J. Whitley
Matthew J. Whitley
TTTimothy H. Tran
Timothy H. Tran
MRMegan Rigby
Megan Rigby
MYMing Yi
Ming Yi
SDSrisathiyanarayanan Dharmaiah
Srisathiyanarayanan Dharmaiah
DSDhirendra K Simanshu
Dhirendra K Simanshu
KRAS , the most frequently mutated oncogene in human cancer, produces two isoforms, KRAS4a and KRAS4b, through alternative splicing. These isoforms differ in exon 4, which encodes the final 15 residues of the G-domain and hypervariable regions (HVRs), vital for trafficking and membrane localization. While KRAS4b has been extensively studied, KRAS4a has been largely overlooked. Our multidisciplinary study compared the structural and functional characteristics of KRAS4a and KRAS4b, revealing distinct structural properties and thermal stability. Position 151 influences KRAS4a’s thermal stability, while position 153 affects binding to RAF1 CRD protein. Nuclear magnetic resonance analysis identified localized structural differences near sequence variations and provided a solution-state conformational ensemble. Notably, KRAS4a exhibits substantial transcript abundance in bile ducts, liver, and stomach, with transcript levels approaching KRAS4b in the colon and rectum. Functional disparities were observed in full-length KRAS variants, highlighting the impact of HVR variations on interaction with trafficking proteins and downstream effectors like RAF and PI3K within cells.

6 March 2026 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CSCarlos Stahlhut
Carlos Stahlhut
AMAnna E. Maciag
Anna E. Maciag
KSKyle A. Sullivan
Kyle A. Sullivan
KSKanchan Singh
Kanchan Singh
NGNadege Gitego
Nadege Gitego
PBPedro J. Beltran
Pedro J. Beltran
Although KRASG12C-specific inhibitors have been introduced, no approved targeted therapies exist for other clinically significant KRAS mutants, including KRASG12D and KRASG12V. We discovered BBO-11818, a potent, selective, orally bioavailable noncovalent pan-KRAS inhibitor capable of targeting multiple KRAS mutants in both the inactive GDP-bound (OFF) and active GTP-bound (ON) states. BBO-11818 binds in the Switch-II/Helix 3 pocket, inducing conformational changes incompatible with effector binding, and demonstrates high-affinity binding to mutant KRAS with strong selectivity over NRAS and HRAS. BBO-11818 potently inhibited MAPK signaling and cellular viability specifically in KRAS-driven lines and produced tumor regressions in KRAS-mutant xenograft models. Combination studies with anti–PD-1, anti-EGFR antibodies, and a RAS:PI3Kα breaker compound showed enhanced efficacy. BBO-11818 has entered phase I clinical trials for patients with various KRAS mutations in colorectal, pancreatic, and lung cancers (NCT06917079). Significance: We discovered BBO-11818, a potent and selective noncovalent KRAS inhibitor with activity against multiple KRAS mutants in both the active (ON) and inactive (OFF) states. BBO-11818 addresses the need for KRAS inhibitors targeting clinically relevant mutants such as KRASG12D and KRASG12V, either as monotherapy or in combination.

30 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MRMohammad Hossein Rohban
Mohammad Hossein Rohban
AFAshley M. Fuller
Ashley M. Fuller
CTCeryl Tan
Ceryl Tan
JGJonathan T. Goldstein
Jonathan T. Goldstein
DSDeepsing Syangtan
Deepsing Syangtan
ACAnne E. Carpenter
Anne E. Carpenter
Identifying chemical regulators of biological pathways is a time-consuming bottleneck in developing therapeutics and research compounds. Typically, thousands to millions of candidate small molecules are tested in target-based biochemical screens or phenotypic cell-based screens, both expensive experiments customized to each disease. Here, our uncustomized, virtual profile-based screening approach instead identifies compounds that match to pathways based on phenotypic information in public cell image data, created using the Cell Painting assay. Our straightforward correlation-based computational strategy retrospectively uncovered the expected, known small molecule regulators for 32% of positive-control gene queries. In prospective, discovery mode, we efficiently identified new compounds related to three query genes, and validated them in subsequent gene-relevant assays, including compounds that phenocopy or pheno-oppose YAP1 overexpression and kill a Yap1-dependent sarcoma cell line. This image profile-based approach could replace many customized labor- and resource-intensive screens and accelerate the discovery of biologically and therapeutically useful compounds. One sentence summary: If a genetic perturbation impacts cell morphology, a computational query can reveal compounds whose morphology “matches”.

17 June 2026
Verified
Other
Open access
CSCarlos Stahlhut
Carlos Stahlhut
AMAnna E. Maciag
Anna E. Maciag
KSKyle A. Sullivan
Kyle A. Sullivan
KSKanchan Singh
Kanchan Singh
NGNadege Gitego
Nadege Gitego
PBPedro J. Beltran
Pedro J. Beltran
Supplementary Figure S7 shows the dose- and time-dependent inhibition of DUSP6 and pERK in KRAS-mutant CDX models treated with BBO-11818, as well as the mean body weight in a KRASG12D CDX model treated with BBO-11818.

17 June 2026
Verified
Other
Open access
PDF file
CSCarlos Stahlhut
Carlos Stahlhut
AMAnna E. Maciag
Anna E. Maciag
KSKyle A. Sullivan
Kyle A. Sullivan
KSKanchan Singh
Kanchan Singh
NGNadege Gitego
Nadege Gitego
PBPedro J. Beltran
Pedro J. Beltran
Supplementary Figure S6 shows densitometry analysis for pERK and pAKT in a western blot experiment in KRASG12D and KRASG12D/A59G cells treated with BBO-11818 or DMSO.

17 June 2026
Verified
Other
Open access
CSCarlos Stahlhut
Carlos Stahlhut
AMAnna E. Maciag
Anna E. Maciag
KSKyle A. Sullivan
Kyle A. Sullivan
KSKanchan Singh
Kanchan Singh
NGNadege Gitego
Nadege Gitego
PBPedro J. Beltran
Pedro J. Beltran
Supplementary Table S2 shows individual EC50 data for the inhibition of ERK phosphorylation in a panel of KRAS-mutant cell lines treated with BBO-11818.